Reporting on DeepMind's November 11 release of AlphaGenome 2, a conditional genomic model predicting cell-type-specific effects of DNA variants, added that the model predicts effect direction at 43% versus 23% for the prior best on 28 immune cell types.
Coverage also noted DeepMind precomputed predictions for trait-linked variants across hundreds of conditions spanning height to type 2 diabetes, and that benchmarks come from DeepMind's own evaluation, with the model not validated for clinical or diagnostic use.